The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
Abstract
Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens. These strains are often multiresistant to several antibiotic classes and are a major cause of serious hospital- and now community-acquired infections and associated morbidity and mortality. As a result of increasing antimicrobial resistance, glycopeptides, such as vancomycin, are widely used as first-line therapy for serious MRSA infections. However, the emergence of glycopeptide tolerance and resistance has complicated treatment and there remains a clinical need for new antibiotics with suitable pharmacokinetic properties with activity against MRSA and other gram-positive pathogens. Infections caused by MRSA and other bacteria usually respond as well to bacteriostatic agents as to bactericidal ones. Nevertheless, there is evidence that rapid bacterial killing has potential clinical advantages over bacteriostatic therapy in certain infections. Daptomycin, the first of the cyclic lipopeptides, shows rapid bactericidal activity against S. aureus, including strains tolerant or resistant to other agents. This review outlines the methods by which bactericidal and bacteriostatic properties are defined and tested, discusses the potential importance of bactericidal therapy in MRSA and other infections and examines the potential role of daptomycin in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since antimicrobial agents are usually classified as bactericidal if the MBC is no more four times the MIC value [41], our results showed that Nisin Z is bactericidal against S. aureus, and Nisin Z with EDTA is bacteriostatic against S. aureus Z.25.2 and P. aeruginosa Z.25.1 in monocultures and dual co-cultures.”
In the citing paper
“However, Nisin Z + EDTA (0.4%) should be considered a valued AMP to kill planktonic S. aureus, as MBC (four to six-fold) was near the limit value to be considered bactericidal [41].”
In the citing paper
“Since antimicrobial agents are usually classified as bactericidal if the MBC is no more four times the MIC value [41], our results showed that Nisin Z is bactericidal against S. aureus, and Nisin Z with EDTA is bacteriostatic against S. aureus Z.25.2 and P. aeruginosa Z.25.1 in monocultures and dual co-cultures.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Vandenesch, F., Naimi, T., Enright, M. C., Lina, G., Nimmo, G. R., Heffernan, H., Liassine, N., Bes, M., Greenland, T., Reverdy, M.-E., et al. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0908.030089 · Cited by 1,727
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Oliveira, D. C., & Lencastre, H. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2155-2161.2002 · Cited by 1,343
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Pankey, G. A., & Sabath, L. D. (2004) · Clinical Infectious Diseases · doi:10.1086/381972 · Cited by 1,201
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Ito, T., Katayama, Y., Asada, K., Mori, N., Tsutsumimoto, K., Tiensasitorn, C., & Hiramatsu, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1323-1336.2001 · Cited by 963
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J. (2005) · The Journal of Infectious Diseases · doi:10.1086/430352 · Cited by 541
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1939 · Cited by 464
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., & Knirsch, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2260-2266.2005 · Cited by 457
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
Graffunder, E. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf009 · Cited by 411
Gonzalez, C., Rubio, M., Romero-Vivas, J., Gonzalez, M., & Picazo, J. J. (1999) · Clinical Infectious Diseases · doi:10.1086/313440 · Cited by 407
Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
Small, P. M., & Chambers, H. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1227 · Cited by 399
Blumberg, P. M., & Strominger, J. L. (1974) · Bacteriological Reviews · doi:10.1128/br.38.3.291-335.1974 · Cited by 381
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
Appelbaum, P. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01344.x · Cited by 376
Eagle, H., & Musselman, A. D. (1948) · Journal of Experimental Medicine · doi:10.1084/jem.88.1.99 · Cited by 375
In Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370
Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania
Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.275-280.2004 · Cited by 370
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
KORZENIOWSKI, O., & SANDE, M. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-4-496 · Cited by 355
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352
Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria
Eng, R. H., Padberg, F. T., Smith, S. M., Tan, E. N., & Cherubin, C. E. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.9.1824 · Cited by 350
Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/421092 · Cited by 332
Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2276-2285.2000 · Cited by 318
Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Smulders, M., Lapetina, E., & Gemmen, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1756 · Cited by 299
Ball, P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.31 · Cited by 290
LaPlante, K. L., & Rybak, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4665-4672.2004 · Cited by 284
Pharmacodynamics of antimicrobial drugs
Levison, M. E. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.012 · Cited by 277
Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus
SORRELL, T. C., PACKHAM, D. R., SHANKER, S., FOLDES, M., & MUNRO, R. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-344 · Cited by 260
Daptomycin‐Resistant, Methicillin‐Resistant Staphylococcus aureus Bacteremia
Mangili, A., Bica, I., Snydman, D. R., & Hamer, D. H. (2005) · Clinical Infectious Diseases · doi:10.1086/428616 · Cited by 256
LEPPER, M. H. (1951) · A.M.A. Archives of Internal Medicine · doi:10.1001/archinte.1951.03810100073006 · Cited by 254
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
A NEW TYPE OF PENICILLIN RESISTANCE OF STAPHYLOCOCCUS AUREUS
(1977) · InPharma · doi:10.1007/bf03284982 · Cited by 253
Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives
Kluytmans-VandenBergh, M. F. Q., & Kluytmans, J. A. J. W. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01341.x · Cited by 243
Nau, R., & Eiffert, H. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.1.95-110.2002 · Cited by 240
Resistance Studies with Daptomycin
Silverman, J. A., Oliver, N., Andrew, T., & Li, T. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1799-1802.2001 · Cited by 234
LEVINE, D. P., CUSHING, R. D., JUI, J., & BROWN, W. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-330 · Cited by 224
The Importance of Bactericidal Drugs: Future Directions in Infectious Disease
Finberg, R. W., Moellering, R. C., Tally, F. P., Craig, W. A., Pankey, G. A., Dellinger, E. P., West, M. A., Joshi, M., Linden, P. K., Rolston, K. V., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/425009 · Cited by 216
The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus Aureus
Walsh, T. R., & Howe, R. A. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160806 · Cited by 215
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Antibiotic Tolerance Among Clinical Isolates of Bacteria
Handwerger, S., & Tomasz, A. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.3.368 · Cited by 206
Marty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., & Pillai, S. K. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.595-597.2006 · Cited by 199
Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C. (2006) · Clinical Infectious Diseases · doi:10.1086/504084 · Cited by 183
Sieradzki, K., & Tomasz, A. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.24.7103-7110.2003 · Cited by 181
Asensio, A., Guerrero, A., Quereda, C., Lizán, M., & Martinez-Ferrer, M. (1996) · Infection Control & Hospital Epidemiology · doi:10.1086/647184 · Cited by 177
Appelbaum, P. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01402.x · Cited by 175
Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection
Louie, A., Kaw, P., Liu, W., Jumbe, N., Miller, M. H., & Drusano, G. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.845-851.2001 · Cited by 172
Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin
Skiest, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.655-656.2006 · Cited by 167
Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy
Sakoulas, G., Moellering, R. C., & Eliopoulos, G. M. (2006) · Clinical Infectious Diseases · doi:10.1086/491713 · Cited by 165
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
Stratton, C. W. (2003) · Emerging infectious diseases · doi:10.3201/eid0901.020172 · Cited by 159
Staphylococcus aureus Endocarditis: Combined Therapy With Vancomycin and Rifampin
Faville, R. J. (1978) · JAMA · doi:10.1001/jama.1978.03290180037019 · Cited by 158
Sculier, J., & Klastersky, J. A. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90662-4 · Cited by 156
Hershberger, E., Donabedian, S., Konstantinou, K., & Zervos, M. J. (2004) · Clinical Infectious Diseases · doi:10.1086/380125 · Cited by 156
Moore, M. R., Perdreau‐Remington, F., & Chambers, H. F. “. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1262-1266.2003 · Cited by 149
Weinstein, M. P., Stratton, C. W., Ackley, A. M., Hawley, H. B., Robinson, P. A., Fisher, B. D., Alcid, D. V., Stephens, D. S., & Reller, L. B. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90436-x · Cited by 147
The need for new therapeutic agents: what is in the pipeline?
SHAH, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01141.x · Cited by 147
Jacqueline, C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg160 · Cited by 134
Effect of protein binding of daptomycin on MIC and antibacterial activity
Lee, B. L., Sachdeva, M., & Chambers, H. F. “. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.12.2505 · Cited by 133
McCullers, J. A., English, B. K., & Novak, R. (2000) · The Journal of Infectious Diseases · doi:10.1086/315216 · Cited by 133
Sakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133
Kowalski, T. J., Berbari, E. F., & Osmon, D. R. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.9.1201 · Cited by 132 · cited 1×
“These infections involve distinct community strains and occur in patients with no history of recent healthcare contact.(9,10) HA-MRSA and CA-MRSA strains are best defined by genetic characterization, based on the staphylococcal cassette chromosome mec (SCCmec) and the distribution of genes encoding antibiotic resistan…”
BackgroundCommunity‐Associated Methicillin‐Resistant Staphylococcus aureus : A Review
Rybak, M. J., & LaPlante, K. L. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.1.74.55620 · Cited by 132
Ginsburg, I. (2002) · Apmis · doi:10.1034/j.1600-0463.2002.1101101.x · Cited by 126
Lamp, K. C., Rybak, M. J., Bailey, E. M., & Kaatz, G. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2709 · Cited by 124
Dandekar, P. K., Tessier, P. R., Williams, P., Nightingale, C. H., & Nicolau, D. P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg337 · Cited by 119
Clinical Significance of Tolerant Strains of Staphylococcus aureus in Patients with Endocarditis
RAJASHEKARAIAH, K. R., RICE, T., RAO, V. S., MARSH, D., RAMAKRISHNA, B., & KALLICK, C. A. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-796 · Cited by 117
Saïd‐Salim, B., Mathema, B., Braughton, K. R., Davis, S., Sinsimer, D., Eisner, W., Likhoshvay, Y., DeLeo, F. R., & Kreiswirth, B. N. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3373-3379.2005 · Cited by 115
Norden, C. W., & Shaffer, M. (1983) · The Journal of Infectious Diseases · doi:10.1093/infdis/147.2.352 · Cited by 114
Critchley, I. A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg130 · Cited by 113
Wilcox, M. H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh088 · Cited by 112
Vancomycin Susceptibility within Methicillin-resistantStaphylococcus aureusLineages
Howe, R. A., Monk, A. B., Wootton, M., Walsh, T. R., & Enright, M. C. (2004) · Emerging infectious diseases · doi:10.3201/eid1005.030556 · Cited by 112
Cottagnoud, P., Pfister, M., Acosta, F., Cottagnoud, M., Flatz, L., Kühn, F., Müller, H.-P., & Stucki, A. N. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3928-3933.2004 · Cited by 109
Gopal, V. (1976) · JAMA · doi:10.1001/jama.236.14.1604 · Cited by 108
Weinstein, M. P., Stratton, C. W., Hawley, H. B., Ackley, A. M., & Reller, L. B. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90688-7 · Cited by 102
Serious Staphylococcal Infections With Strains Tolerant to Bactericidal Antibiotics
Denny, A. E., Peterson, L. R., Gerding, D. N., & Hall, W. H. (1979) · Archives of Internal Medicine · doi:10.1001/archinte.1979.03630460058018 · Cited by 98
Monnet, D. L. (1998) · Infection Control and Hospital Epidemiology · doi:10.1086/647872 · Cited by 98
Quinupristin-Dalfopristin Resistance among Gram-Positive Bacteria in Taiwan
Luh, K., Hsueh, P., Teng, L., Pan, H., Chen, Y.-C., Lu, J., Wu, J., & Ho, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3374-3380.2000 · Cited by 97
Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms
Cha, R., Grucz, R. G., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1598-1603.2003 · Cited by 95
Shear, N., & Litt, J. Z. (2004) · CRC Press eBooks · doi:10.3109/9780203492079-157 · Cited by 93
Cantoni, L., Glauser, M. P., & Billé, J. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2348 · Cited by 89
Sader, H. S., Fritsche, T. R., & Jones, R. N. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01491-05 · Cited by 86
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 79
Bacterial eradication in the treatment of otitis media
Dagan, R., & Leibovitz, E. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00394-8 · Cited by 76
Epidemiology and Clinical Impact of Glycopeptide Resistance in Staphylococcus aureus
Ruef, C. (2004) · Infection · doi:10.1007/s15010-004-4124-7 · Cited by 75
Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Thornsberry, C., Sahm, D. F., & Karlowsky, J. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1689-1693.2003 · Cited by 75
Koehl, J. L., Muthaiyan, A., Jayaswal, R. K., Kerstin Ehlert, B., Labischinski, H., & Wilkinson, B. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3749-3757.2004 · Cited by 74
Shelburne, S. A., Musher, D. M., Hultén, K. G., Ceasar, H., Lu, M. Y., Bhaila, I., & Hamill, R. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.4016-4019.2004 · Cited by 70
Kim, K. S., & Anthony, B. F. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.6.1075 · Cited by 61
Kaatz, G. W., Seo, S. M., Reddy, V. N., et al. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.11.2081 · Cited by 61
Nau, R., & Eiffert, H. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2005.01.001 · Cited by 56
Voorn, G. P., Kuyvenhoven, J. P., Goessens, W. H. F., Schmal-Bauer, W. C., Broeders, P. H. M., Thompson, J., & MICHEL, M. F. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.487 · Cited by 46
Glycopeptide tolerance in bacteria causing endocarditis
Perry, J. D., Jones, A. L., & Gould, F. K. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.1.121 · Cited by 43
Rodriguez, C. A., Atkinson, R., Bitar, W., Whitney, C. G., Edwards, K. M., Mitchell, L., Li, J., Sublett, J. E., Li, C., Liu, T., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/424467 · Cited by 43
Ike, Y., Arakawa, Y., Ma, X., Tatewaki, K., Nagasawa, M., Tomita, H., Tanimoto, K., & Fujimoto, S. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.12.4445-4451.2001 · Cited by 40
The advance of bacterididal drugs in the treatment of infection
Alder, J. D., & Eisenstein, B. I. (2004) · Current Infectious Disease Reports · doi:10.1007/s11908-004-0042-1 · Cited by 39
Oh, W. S., Ko, K. S., Song, J., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5176-5178.2005 · Cited by 33
Update on daptomycin: the first approved lipopeptide antibiotic
Lee, S. Y., Fan, H. W., Kuti, J. L., & Nicolau, D. P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1381 · Cited by 30
A Mouse Peritonitis Model for the Study of Glycopeptide Efficacy in GISA Infections
Doménech, A., Ribes, S., Cabellos, C., et al. (2004) · Microbial Drug Resistance · doi:10.1089/mdr.2004.10.346 · Cited by 24
Voorn, G. P., Thompson, J., Goessens, W. H. F., et al. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.3.585 · Cited by 11
Value of the serum bactericidal test in management of patients with bacterial endocarditis
Mellors, J. W., COLEMAN, D. L., & Andriole, V. T. (1986) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02013472 · Cited by 9
Cited by
Ecological effects of antibiotics on natural ecosystems: A review
Grenni, P., Ancona, V., & Barra Caracciolo, A. (2018) · Microchemical Journal · doi:10.1016/j.microc.2017.02.006 · Cited by 1,257
Comprehensive review of antimicrobial activities of plant flavonoids
Górniak, I., Bartoszewski, R., & Króliczewski, J. (2019) · Phytochemistry Reviews · doi:10.1007/s11101-018-9591-z · Cited by 1,195
Alkaloids: An overview of their antibacterial, antibiotic-enhancing and antivirulence activities
Cushnie, T. P. T., Cushnie, B., & Lamb, A. J. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.001 · Cited by 894
Yoon, B., Jackman, J., Valle-González, E., & Cho, N.-J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041114 · Cited by 637
Unravelling the collateral damage of antibiotics on gut bacteria
Maier, L., Goemans, C. V., Wirbel, J., Kuhn, M., Eberl, C., Pruteanu, M., Müller, P., Garcia-Santamarina, S., Cacace, E., Zhang, B., et al. (2021) · Nature · doi:10.1038/s41586-021-03986-2 · Cited by 391
Metadata
- Authors
- French, G. L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-20
- Volume
- 58
- Issue
- 6
- Pages
- 1107-1117
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2096541421
- Cited by
- 441
- References
- 116
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.